Watkins, L. V.
Dunstall, H.
Musicha, C.
Lawthom, C.
John, K.
Bright, C.
Richings, C.
Harding, K.
Moon, S.
Pape, S. E.
Winterhalder, R.
Allgar, V.
Thomas, R. H.
McLean, B.
Laugharne, R.
Shankar, Rohit http://orcid.org/0000-0002-1183-6933
Article History
Received: 2 August 2023
Revised: 17 August 2023
Accepted: 18 August 2023
First Online: 23 August 2023
Declarations
:
: RHT has received honoraria from Angelini, Bial, Biocodex, Eisai, Jazz, LivaNova, Neuraxpharm, Sanofi, Takeda, UCB Pharma and Zogenix, meeting support from Angelini, Bial, UCB Pharma, unrestricted funding support from Angelini and UnEEG and a joint working partnership with UCB Pharma. CL has received consultancy fees from Lundbeck, and speaker fees from Sanovi. RS has received institutional and research support from LivaNova, UCB, Eisai, Veriton Pharma, Bial, Angelini, UnEEG and Jazz/GW pharma outside the submitted work. He holds grants from NIHR AI, SBRI and other funding bodies all outside this work. No other author has any declared conflict of interest related to this paper.
: We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.